A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Phase 2

Not yet recruiting

• Conditions: Gastric Cancer
• Interventions: Drug: Fruquintinib + RC48

• Registration Number: NCT05241899
• Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Brief Summary

Although Pembrolizumab plus trastuzumab and chemotherapy is the standard of care for first-line treatment of HER2-positive advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer,there is no established therapy in the second-line setting.

RC48 showed promising activity with manageable safety in patients with HER2-overexpressing, advanced G/GEJ cancer who have previously received at least two lines of chemotherapy.Fruquintinib in combination with Paclitaxel demonstrated encouraging preliminary clinical antitumor activity in patients with advanced GC in ph1b/2 study.

This study is aimed to evaluate the efficacy and safety of Fruquintinib in combination with RC48 in the treatment of previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer.

Detailed Description

This study is a phase II, single arm study with main purpose to evaluate the safety, tolerability and efficacy of Fruquintinib in combination with RC48 in the treatment of previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer.

All eligible patients received Fruquintinib (4mg orally, once daily for 3 wks on/1 wk off) combined with of RC48( 2.5mg/kg by intravenous infusion during 30-90 min every 2 weeks) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).

Study Timeline

• Status Verified: 2022-02
• Study First Submitted: 2022-02-06
• Study First Submitted QC: 2022-02-06
• Last Update Submitted: 2022-02-06
• Study First Posted: 2022-02-16
• Last Update Posted: 2022-02-16
• Study Start: 2022-05-07
• Primary Completion: 2023-05-07
• Study Completion: 2025-05-07

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

1. Aged 18-75years (inclusive);
2. Body weight ≥40 kg;
3. Physical status score (ECOG score) 0-1;
4. Expected survival >12 weeks.;
5. At least one measurable lesion (according to RECIST1.1);
6. Histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic HER2 positive G/GEJ cancer;
7. HER2-positive defined as either immunohistochemistry (IHC) 3+ or IHC 2+ in combination with in-situ hybridization positive (ISH+) or fluorescent in-situ hybridization (FISH), as assessed by central review on primary or metastatic tumor;
8. Fail in previous first-line standard chemotherapy;
9. prior therapy does not need to have included a HER2-directed therapy;
10. Adjuvant or neoadjuvant therapy for AGC is allowed.
11. Absence of major post-operative complications or other clinical conditions that, in the opinion of the investigator, would contraindicate adjuvant chemotherapy 8. Adequate hematological function defined by absolute neutrophil count (ANC) ≥1.5 × 109/L, platelet count ≥100 × 109/L, and hemoglobin ≥9 g/dL (blood transfusion before recruitment is allowed)
12. Adequate hepatic function defined by a total bilirubin level ≤1.5 × the upper limit of normal (ULN) range and AST and ALT levels ≤2.5 × ULN 10. Adequate renal function defined by an estimated creatinine clearance ≥30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method) 11. Negative serum or urine pregnancy test at screening for women of childbearing potential 12. Fertile men and women must agree to take highly effective contraceptive precautions during, and for 6 months after the last dose of chemotherapy or for 1 month after the last dose of Tislelizumab

Exclusion Criteria

1. An interval shorter than 21 days from the last dose of chemotherapy or HER2-directed therapy until the time of randomization
2. Prior treatment with RC48, Fruquintinib, or apatinib either as single agents or as part of a treatment regimen.
3. Treatment with any investigational anticancer drug within 21 days of the first study treatment administration
4. More than one prior line of therapy for advanced G/GEJ cancer;
5. History of other malignancy within the previous 5 years except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other malignancies with an expected curative outcome
6. Brain metastases that are untreated or symptomatic or require any radiation, surgery, or steroid therapy to control symptoms from brain metastases within 1 month of randomization
7. Peripheral neuropathy Grade >/=2
8. Uncontrolled cardiopulmonary dysfunction (e.g., high blood pressure, serious cardiac arrhythmia)
9. Other current, severe, uncontrolled systemic disease (e.g., clinically significant metabolic disease, wound healing disorders, ulcers)
10. Clinically significant bleeding within 30 days before enrollment
11. For female participants, current pregnancy or lactation
12. Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment
13. Infection with Human immunodeficiency virus (HIV) or hepatitis B virus, hepatitis C virus

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Fruquintinib + RC48	Fruquintinib + RC48	Fruquintinib + RC48

Primary Outcome Measures

Name	Time	Method
Progression free survival (PFS)	from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year	Tumor assessment will be performed using radiography method every 8 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1

Secondary Outcome Measures

Name	Time	Method
Overall survival (OS)	from randomization until death due to any cause, assessed up to 3 year	every two months follow up after EOT observation period at 30 days after the last medication
Objective response rate (ORR)	from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year	Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1
Disease control rate (DCR)	from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year	Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1
Safety and tolerance evaluated by incidence, severity and outcomes of AEs	from first dose to 30 days post the last dose	Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.03

Trial Locations

Locations (1)

The First Affiliated Hospital of Zhengzhou University; 🇨🇳 Zhengzhou, Henan, China